Shots: Astellas to initiate global BRIGHT SKY program which includes three P-III studies (SKYLIGHT 1, SKYLIGHT 2 and SKYLIGHT 4) and will assess fezolinetant (30/45mg, qd) in postmenopausal women with […]readmore
Tags : BRIGHT SKY
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US